Thursday, July 3, 2025 7/3/2025

Epigenomic and transcriptomic markers of aggressive prostate cancer among African American men

Award Number: K07CA230182
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: TRAINING/TRAINEESHIP
PERIOD OF PERFORMANCE START DATE: 07/15/2018
PERIOD OF PERFORMANCE END DATE: 06/30/2025

Group Awards By:

View Award Description

Epigenomic and transcriptomic markers of aggressive prostate cancer among African American men - PROJECT SUMMARY African American men experience a disproportionate burden of aggressive prostate cancer and prostate cancer mortality when compared with European American men. The underlying reason for the disparity is unclear and the ability to predict an individual patient’s disease trajectory remains limited. This makes treatment decisions difficult, particularly as available treatments range widely from active surveillance to radical prostatectomy, which can have severe consequences such as urinary incontinence and erectile dysfunction. There is growing evidence to support the potential of DNA methylation (DNAm) and RNA expression markers in prostate tumors to enhance prostate cancer prognostication beyond clinical factors, but few studies to date have focused on African American men. The present pilot study will leverage a unique patient population (>40% African American) and archival radical prostatectomy prostate tissue from the University of Maryland Greenebaum Comprehensive Cancer Center. Aims 1 and 2 propose to leverage array-based technology to investigate whether DNAm and RNA expression markers can discriminate between aggressive (total Gleason score>=7) and non-aggressive prostate cancer (total Gleason score<7) in African American men. We will use Gleason score as our endpoint because it is available for all samples and because recent studies have supported its utility as an intermediate endpoint in the discovery of prognostic markers. Aim 3 proposes integrated analyses of DNAm and RNA expression data to investigate the hypothesis that some DNAm markers are associated with aggressive disease independently of expression, thereby providing unique prognostic information. The K07 mechanism will allow me to receive essential training in the integration/application of tumor tissue biomarkers in epidemiological studies and analysis of high-dimensional data under the guidance of a strong team of mentors with synergistic expertise in molecular epidemiology, prostate tumor biomarkers, high dimensional data analysis and predictive oncology modeling. This project will also include an additional advisor who is a genitourinary oncologist and basic science researcher in prostate cancer and will contribute to the interpretation and assessment of clinical significance of findings. My previous research has focused on blood- based biomarkers in targeted genomic regions and I will greatly benefit from specialized training in tumor tissue markers and expanding to high-dimensional data as I move towards independence in molecular cancer epidemiology. Moreover, this study will provide preliminary data that will build toward a larger (R01) application in which I will integrate epigenomic and transcriptomic data for the discovery of novel biomarkers of aggressive prostate cancer among African American men. My long-term goal is to lead studies that will promote improved public health and reduce disparities in cancer outcomes through personalized medicine.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2024 ( Subtotal = $0 )
2024	2023	UNIVERSITY OF MARYLAND, BALTIMORE	220 ARCH ST OFC LEVEL2	BALTIMORE	MD	21201	BALTIMORE CITY	USA	Cancer Research Manpower	001	5	7/15/2024	SUPPLEMENT FOR EXPANSION	$0
2024	2022	UNIVERSITY OF MARYLAND, BALTIMORE	220 ARCH ST OFC LEVEL2	BALTIMORE	MD	21201	BALTIMORE CITY	USA	Cancer Cause and Prevention Research	000	5	7/15/2024	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2023 ( Subtotal = $135,511 )
2023	2023	UNIVERSITY OF MARYLAND, BALTIMORE	220 ARCH ST OFC LEVEL2	BALTIMORE	MD	21201	BALTIMORE CITY	USA	Cancer Research Manpower	001	5	8/9/2023	SUPPLEMENT FOR EXPANSION	$135,511
2023	2022	UNIVERSITY OF MARYLAND, BALTIMORE	220 ARCH ST OFC LEVEL2	BALTIMORE	MD	21201	BALTIMORE CITY	USA	Cancer Cause and Prevention Research	000	5	8/9/2023	NON-COMPETING CONTINUATION	$0
														Subtotal = $135,511

Issue Date FY: 2022 ( Subtotal = $138,440 )
2022	2022	UNIVERSITY OF MARYLAND	220 ARCH ST RM 02148	BALTIMORE	MD	21201	BALTIMORE CITY	USA	Cancer Cause and Prevention Research	000	5	6/30/2022	NON-COMPETING CONTINUATION	$138,440
														Subtotal = $138,440

Issue Date FY: 2021 ( Subtotal = $138,440 )
2021	2021	UNIVERSITY OF MARYLAND	220 ARCH ST RM 02148	BALTIMORE	MD	21201	BALTIMORE CITY	USA	Cancer Cause and Prevention Research	000	4	6/30/2021	NON-COMPETING CONTINUATION	$138,440
														Subtotal = $138,440

Issue Date FY: 2020 ( Subtotal = $138,440 )
2020	2020	UNIVERSITY OF MARYLAND	220 ARCH ST RM 02148	BALTIMORE	MD	21201	BALTIMORE CITY	USA	Cancer Cause and Prevention Research	000	3	6/29/2020	NON-COMPETING CONTINUATION	$138,440
														Subtotal = $138,440

Issue Date FY: 2019 ( Subtotal = $138,104 )
2019	2019	UNIVERSITY OF MARYLAND	220 ARCH ST RM 02148	BALTIMORE	MD	21201	BALTIMORE CITY	USA	Cancer Cause and Prevention Research	000	2	6/25/2019	NON-COMPETING CONTINUATION	$138,104
														Subtotal = $138,104

Issue Date FY: 2018 ( Subtotal = $138,094 )
2018	2018	UNIVERSITY OF MARYLAND	220 ARCH ST RM 02148	BALTIMORE	MD	21201	BALTIMORE CITY	USA	Cancer Cause and Prevention Research	001	1	7/10/2018	NEW	-$346
2018	2018	UNIVERSITY OF MARYLAND	220 ARCH ST RM 02148	BALTIMORE	MD	21201	BALTIMORE CITY	USA	Cancer Cause and Prevention Research	000	1	7/6/2018	NEW	$138,440
														Subtotal = $138,094

Grand Total All Awards = $827,029

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Epigenomic and transcriptomic markers of aggressive prostate cancer among African American men

Award Number: K07CA230182

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: TRAINING/TRAINEESHIP

PERIOD OF PERFORMANCE START DATE: 07/15/2018

PERIOD OF PERFORMANCE END DATE: 06/30/2025

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer